Cerity Partners LLC Has $592,000 Holdings in Smith & Nephew plc (NYSE:SNN)

Cerity Partners LLC grew its position in Smith & Nephew plc (NYSE:SNN) by 31.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,001 shares of the medical equipment provider’s stock after purchasing an additional 4,552 shares during the quarter. Cerity Partners LLC’s holdings in Smith & Nephew were worth $592,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in SNN. Mather Group LLC. increased its position in Smith & Nephew by 9,735.3% during the 2nd quarter. Mather Group LLC. now owns 1,672 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 1,655 shares during the period. Simplicity Wealth LLC increased its position in Smith & Nephew by 13.4% during the second quarter. Simplicity Wealth LLC now owns 16,848 shares of the medical equipment provider’s stock worth $417,000 after acquiring an additional 1,993 shares during the period. Lorne Steinberg Wealth Management Inc. raised its stake in Smith & Nephew by 53.6% in the 2nd quarter. Lorne Steinberg Wealth Management Inc. now owns 231,045 shares of the medical equipment provider’s stock worth $5,725,000 after purchasing an additional 80,650 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Smith & Nephew by 1,894.3% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,735 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 1,648 shares during the period. Finally, Argonautica Private Wealth Management Inc. grew its position in shares of Smith & Nephew by 6.3% during the 2nd quarter. Argonautica Private Wealth Management Inc. now owns 10,244 shares of the medical equipment provider’s stock worth $254,000 after purchasing an additional 605 shares in the last quarter. Institutional investors own 25.64% of the company’s stock.

Smith & Nephew Price Performance

Shares of NYSE:SNN opened at $25.36 on Friday. The firm has a 50 day moving average of $27.05 and a 200-day moving average of $27.87. Smith & Nephew plc has a 12 month low of $23.65 and a 12 month high of $31.72. The company has a current ratio of 2.51, a quick ratio of 1.11 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $11.09 billion, a PE ratio of 12.94, a PEG ratio of 1.40 and a beta of 0.84.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on SNN shares. StockNews.com downgraded shares of Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut Smith & Nephew from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Finally, Berenberg Bank downgraded Smith & Nephew from a “buy” rating to a “hold” rating in a research report on Wednesday, November 6th.

Smith & Nephew Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.